RE
RENX.LSE Renalytix AI plc
- Market cap
- GBX 36.5M
- P/E
- -
- P/B
- 8.06x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is RENX.LSE undervalued?
Graham numberThe Graham number of Renalytix AI plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Renalytix AI plc fundamental analysis
No fundamental analysis for Renalytix AI plc yet.
Renalytix AI plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Renalytix AI plc
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The co…
Full company profileRenalytix AI plc financial statements
Renalytix AI plc annual financial statements
| Item | 2016 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 55.5B | - | 0.00 | 58.3B | 1.49M | 2.97M | 59.6B | 2.29M | 3.00M | 3.01M |
| Gross Profit | 23.7B | - | -31.0K | -74.0K | 633K | 874K | 25.2B | 156K | 1.20M | 1.10M |
| Operating Income | 8.11B | -418K | -42.3M | -10.3M | -31.9M | -53.2M | 10.1B | -29.6M | -17.2M | -14.0M |
| EBITDA | 9.65B | -418K | -6.87M | -10.2M | -30.8M | -52.7M | 11.1B | -28.5M | -21.3M | -13.8M |
| Net Income | 5.46B | -1.25M | -42.3M | -9.84M | -34.7M | -45.3M | 6.49B | -33.5M | -20.4M | -14.2M |
| EPS | 1.91 | -0.03 | -0.99 | -0.17 | -0.49 | -0.61 | 67 | -0.31 | -0.21 | -0.03 |
| Balance Sheet | ||||||||||
| Total Assets | 59.4B | 56.6K | 28.9M | 41.3M | 103M | 50.1M | 75.3B | 7.97M | 6.10M | 4.62M |
| Total Liabilities | 41.5B | 66.0K | 755K | 5.34M | 7.48M | 19.5M | 54.5B | 15.8M | 13.1M | 11.0M |
| Shareholders' Equity | 24.9B | -349K | 8.55M | 15.9M | 71.5M | 30.6M | 18.1B | -7.85M | -7.00M | -6.33M |
| Cash & Short-term Investments | 4.34B | 82.0K | 9.20M | 14.3M | 74.5M | 41.3M | 5.85B | 5.40M | 3.70M | 1.41M |
| Total Debt | - | 66.0K | - | 622K | 352K | 12.3M | 29.3B | 8.54M | 8.30M | 5.73M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 7.05B | -422K | -6.16M | -10.1M | -24.6M | -45.7M | 9.43B | -30.1M | -17.9M | -10.9M |
| Capital Expenditure | 1.80B | 0.00 | 13.0M | 1.31M | 1.63M | 694K | 1.50B | 4.00K | 6.29 | 100K |
| Free Cash Flow | 5.24B | -422K | -17.0M | -11.4M | -26.3M | -46.4M | 7.92B | -30.1M | -17.9M | -11.0M |
| Ratios | ||||||||||
| ROE | 21.9% | - | -494.7% | -61.9% | -48.6% | -147.9% | 35.8% | - | - | - |
| ROA | 9.2% | -2,214.5% | -146.3% | -23.8% | -33.9% | -90.4% | 8.6% | -419.7% | -334.4% | -307.9% |
| Net Profit Margin | 9.8% | - | - | 0.0% | -2,329.0% | -1,524.4% | 10.9% | -1,461.6% | -680.0% | -473.3% |
| Debt to Equity | - | - | - | 0.04x | 0.00x | 0.40x | 1.62x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Renalytix AI plc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | 4.36B | 45 | 67.3% |
| 2022 | USD 5.10B | 69 | - |
| 2021 | USD 5.23B | 73 | - |
| 2020 | GBX 4.72B | 80 | - |
| 2019 | GBX 4.66B | 109 | - |
| 2018 | - | - | - |
| 2016 | 3.61B | 1.26 | 66.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Renalytix AI plc
- Insiders 18.31%
- Institutions 47.22%
- Public & others 34.47%
- Shares outstanding 670M
- Free float 312M
Renalytix AI plc company profile
- Company name
- Renalytix AI plc
- Ticker
- RENX.LSE
- ISIN
- GB00BYWL4Y04
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 46
- Fiscal year end
- June
- Address
- 2 Leman Street, London, United Kingdom, E1W 9US
- Phone
- 646 397 3970
- Website
- renalytix.com
About Renalytix AI plc
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The company's products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. It has a license agreement with Mount Sinai Health System to develop and commercialize its products in connection with the application of artificial intelligence for the diagnosis of kidney disease. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. The company was incorporated in 2018 and is based in London, the United Kingdom.
Renalytix AI plc management
5- Mr. James R. McCullough M.B.A.CEO & Director · born 1968
- Mr. Fergus FlemingCTO & Executive Director · born 1967
- Mr. Howard B. Doran Jr.President · born 1961
- Mr. Joel R. Jung MBAChief Financial Officer · born 1958
- Dr. Michael J. Donovan M.D., Ph.D.Chief Medical Officer · born 1954